| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.85▼ | 1.83▼ | 1.85▼ | 1.90▼ | 1.71▲ |
| MA10 | 1.84▼ | 1.85▼ | 1.89▼ | 1.87▼ | 1.52▲ |
| MA20 | 1.84▼ | 1.90▼ | 1.91▼ | 1.73▲ | 1.39▲ |
| MA50 | 1.86▼ | 1.91▼ | 1.90▼ | 1.51▲ | 3.47▼ |
| MA100 | 1.91▼ | 1.90▼ | 1.79▲ | 1.39▲ | 5.07▼ |
| MA200 | 1.91▼ | 1.78▲ | 1.67▲ | 2.75▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.004▲ | -0.009▼ | -0.016▼ | 0.006▲ | 0.237▲ |
| RSI | 43.248▼ | 33.848▼ | 39.252▼ | 59.158▲ | 45.497▼ |
| STOCH | 43.056 | 7.962▼ | 11.574▼ | 75.408 | 36.120 |
| WILL %R | -91.667▼ | -96.774▼ | -97.368▼ | -37.255 | -57.151 |
| CCI | -57.436 | -66.470 | -92.620 | 54.329 | 137.242▲ |
|
Wednesday, October 01, 2025 01:44 PM
Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary ...
|
|
Wednesday, August 13, 2025 01:15 PM
Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti-tumor activity -- ACR-368 in a registrational-intent Phase 2 study in endometrial cancer and ACR ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 10/10/25 | 1.97 | 2.01 | 1.82 | 1.83 | 738,286 |
| 09/10/25 | 1.87 | 2.02 | 1.87 | 1.96 | 436,630 |
| 08/10/25 | 1.93 | 2.00 | 1.86 | 1.88 | 365,329 |
| 07/10/25 | 1.92 | 1.96 | 1.82 | 1.91 | 711,070 |
| 06/10/25 | 1.95 | 1.985 | 1.90 | 1.91 | 424,490 |
| 03/10/25 | 1.88 | 1.98 | 1.84 | 1.91 | 559,804 |
| 02/10/25 | 1.84 | 1.90 | 1.77 | 1.86 | 282,418 |
| 01/10/25 | 1.82 | 1.8647 | 1.78 | 1.81 | 390,652 |
| 30/09/25 | 1.77 | 1.83 | 1.70 | 1.81 | 539,479 |
| 29/09/25 | 1.69 | 1.84 | 1.6608 | 1.82 | 996,867 |
|
|
||||
|
|
||||
|
|